Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine.
about
Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis.Synovial fluid and serum concentrations of aminoterminal propeptide of type III procollagen in healthy volunteers and patients with joint diseaseSeromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy.A pathological role for damaged hyaluronan in synovitis.Markers of collagen and basement membrane metabolism in sera of patients with progressive systemic sclerosis.Serum hyaluronan and aminoterminal propeptide of type III procollagen: variation with age.Relationship between procollagen III peptide serum levels, synovitis of weight bearing joints and disability in rheumatoid arthritis.Galectin-3 is Persistently Increased in Early Rheumatoid Arthritis (RA) and Associates with Anti-CCP Seropositivity and MRI Bone Lesions, While Early Fibrosis Markers Correlate with Disease Activity.Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in early rheumatoid arthritis.Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment.Serum Levels of Aminoterminal Type III Procollagen Peptide and Hyaluronan Predict Mortality in Systemic Sclerosis
P2860
Q33578499-2C1FEE37-C291-4974-8BA3-D8F95233A977Q33578643-BC47D27B-0284-4F06-B091-DEA1C8655219Q34409098-A7EAF550-BB0E-4C09-9ECD-643E674A4E0BQ37691072-F6FC9A67-948D-4034-A213-76F2B5F70C68Q41236919-984C0D64-505F-485D-AD6A-45C1D20EC072Q44530063-4F23B963-8347-4E23-89D4-16C6B0100835Q47435930-4306256E-B267-468C-A318-FCCF14FB414AQ47679282-59505E3D-024A-4FA7-8AFE-6852DBE82FB7Q47849262-D1CFAA1D-DB2B-4058-97C7-40A66613F8D0Q52732629-D31864B2-43BC-461A-AB31-D356DD73A9D1Q57832139-57586B71-BB67-4823-88C1-13A678EF83BF
P2860
Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine.
description
1988 nî lūn-bûn
@nan
1988 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Serum amino terminal type III ...... enicillamine, or azathioprine.
@ast
Serum amino terminal type III ...... enicillamine, or azathioprine.
@en
Serum amino terminal type III ...... enicillamine, or azathioprine.
@nl
type
label
Serum amino terminal type III ...... enicillamine, or azathioprine.
@ast
Serum amino terminal type III ...... enicillamine, or azathioprine.
@en
Serum amino terminal type III ...... enicillamine, or azathioprine.
@nl
prefLabel
Serum amino terminal type III ...... enicillamine, or azathioprine.
@ast
Serum amino terminal type III ...... enicillamine, or azathioprine.
@en
Serum amino terminal type III ...... enicillamine, or azathioprine.
@nl
P2093
P2860
P356
P1476
Serum amino terminal type III ...... enicillamine, or azathioprine.
@en
P2093
Bentsen KD
Engström-Laurent A
Hørslev-Petersen K
Lorenzen I
P2860
P304
P356
10.1136/ARD.47.2.116
P407
P577
1988-02-01T00:00:00Z